VALUE-ADDED PARTNERSHIPS & COLLABORATIONS
Research, Clinical trial expertise, Encrypted software, Government Funding
 |
 |
 |
| Pre-clinical Trials | Government Grants | Clinical Trial Expertise |
 |
 |
 |
| Pre-clinical MES Model | Government Grants | Clinical Study Partner |
Pre-Clinical Trials: Pre-clinical trials on rodents were successfully completed at Western University. A pre-clinical MES model of epilepsy conducted on mice at the Ontario Brain Institute revealed that CQ-001 demonstrated a 35% increase in potency compared to isolated cannabidiol alone. This indicates that the drug is significantly more effective at protecting against seizure activity.
Synergistic Effect: The combination of cannabidiol and the proprietary API composition in CQ-001 demonstrated potentiation, resulting in an effect greater than the sum of the individual effects of cannabidiol or the proprietary API alone. This suggests the potential for using lower dosages to achieve similar efficacy, potentially translating to a safer side effect profile.
Accumulated Expertise: To commercialize and obtain relevant regulatory approvals for CQ-001, CanaQuest has gathered a strong team with extensive experience in cannabinoid therapeutics, including:
-
- Acting Chief Scientific Officer – Dr. Jordyn Stuart, Ph.D., BS, BS: With 12 years of pre-clinical cannabinoid research experience, including 6 years with Greenwich Biosciences (subsidiary of GW Pharma, now Jazz Pharma), Dr. Stuart has been involved in the launch of Epidiolex®.
- Chairman of Advisory Board – Dr. Paul Dick, DVM, MSc: With over 30 years of experience in the pharmaceutical and animal health industries, Dr. Dick has served on several boards, including the Animal Health Institute and the Ontario Veterinary Medical Association.
- Interim Chief Operating Officer – Eddie Francis, MS: With a background in Molecular Biology and Oncology, Eddie has over 10 years of experience in the natural therapeutic sector and 20 years in the private sector, focusing on mental health and wellness initiatives.
We have also secured ongoing relationships with trusted legal, regulatory, and compliance advisors who will help move our business forward.
Regulatory Approval Process: CanaQuest is positioned to submit New Drug Applications (NDAs) to Health Canada and the US FDA for Phase II/III clinical trials. Approval is projected to take approximately 2 years in Canada and 3 years in the US. The company acknowledges the inherent risks and uncertainties involved in the regulatory approval process, including regulatory requirements, clinical trial outcomes, and potential unforeseen challenges.
Partnerships: CanaQuest has established partnerships with Neeka Health for clinical trial expertise and the NHL Alumni Association for clinical studies. These partnerships will investigate the potential applications of CQ-001 across various indications, paving the way for future clinical trials.
